Description: This three-part series provides an overview of the rapidly evolving and dynamic gene and cellular therapy landscape, from the clinical, historical, and risk transfer perspectives. It covers the actuarial considerations in pricing cell and gene insurance and reinsurance, the value assessment of the therapies, manufacturer pricing, and reinsurance cost.

Description: COVID has washed over healthcare like a tsunami. According to Medicare actuaries, trends have been turned upside down in 2021, but will reverse back in 2023 as medical costs rebound. It is more prudent to base projections on long run trends for a period after the storm, extrapolating from 2026 forward, leaving the intervening turbulence (years 2022 -2025) mostly unspecified.

Description: The Society of Actuaries Research Institute’s Aging and Retirement Strategic Research Program is pleased to release three essays addressing the actuarial impact of mental health issues in retirement.

Description: The Inflation Reduction Act represents the most significant changes to the Part D program since its inception 20 years ago. The implications will not only alter the benefits offered by Medicare Advantage (MAPD) and Prescription Drug Plans (PDP) but will alter the Part D cash flows and the seasonality of such amounts for interim reporting periods. In this session, we will provide a brief overview of the IRA changes and dive into how the changes could impact the 2008 Medicare Part D Accounting Practice Note.

Description: This session will focus on long term disability insurance reserving practices. It will address current practices in calculating claim reserves and may include topics such as the following: Relevant Actuarial Guidelines, Studies used to evaluate claim termination experience and reserve margins, Estimation of future offsets, Mortality improvement

Description: Virtual - Session 2C: Innovative Care Models for Medicare & Medicaid Dually - Eligible Populations

Description: Session 6D: Breaking Barriers - A Multidimensional Approach to Behavioral Healthcare Access

Description: Session 9B: Negotiated Drugs - How the IRA Program Impacts the PD Ecosystem

Description: Session 6F: Consumer Value - Can New Health Plan Designs Improve Cost, Quality and Transparency?

Description: Session 5E: The Health Societal Purpose of the Actuarial Profession